The latest edition of Meds Pipeline Monitor, from the Patented Medicine Prices Review Board, features a selection of new medicines undergoing clinical evaluation or in pre-registration that may gain market authorization in Canada in the future. There were 10,501 drugs in the pipeline as of August 2025. The full release is available online. Contact PMPRB.MediaCentre-CentreMedias.CEPMB@pmprb-cepmb.gc.ca.
Minister of Health Marjorie Michel (Papineau, Que.) tabled the 2024 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the Senate and the House of Commons. The 2024 Annual Report reviews trends in the prices and sales of patented medicines in Canada. Sales of patented medicines in 2024 were $22.1 billion and accounted … Read more
The latest edition of the Patented Medicine Prices Review Board (PMPRB) CompassRx report shows that prescription drug expenditure for public drug plans grew by 7.4 per cent in 2022/23 to reach $14.1 billion, compared to $13.2 billion in 2021/22. Drugs costing over $10,000 annually accounted for over one third of total drug costs for the public drug … Read more
The Patented Medicine Prices Review Board (PMPRB) published its new Guidelines for PMPRB Staff. They will take effect on Jan. 1, 2026. The Guidelines explain the new two-step process used by PMPRB staff to monitor and review drug prices by comparing them to the prices in other countries or to other similar treatments in Canada. … Read more
The Patented Medicine Prices Review Board (PMPRB) published the 9th edition of its annual Meds Entry Watch report. Like last year, the analysis finds that the number of new medicines launched in Canada is higher than the median for Organisation for Economic Co-operation and Development (OECD) countries. Most new medicines come to market with high treatment costs (over $10,000 per year or $5,000 per … Read more
Patented Medicine Prices Review Board (PMPRB) Chairperson Thomas Digby has stepped down from his role, effective March 6, 2025, to pursue other opportunities. PMPRB Vice-Chairperson Anie Perrault has assumed the duties of acting Chairperson until a permanent replacement for Digby is appointed by the Governor in Council. The full release is available online. Contact PMPRB.MediaCentre-CentreMedias.CEPMB@pmprb-cepmb.gc.ca.
The Patented Medicine Prices Review Board has published its latest report, Private Drug Plans in Canada: Expenditure Report, 2018–2023. This report provides insight into the factors driving growth in prescription drug costs for private drug plans in 2023, as well as a retrospective review of trends in private drug plan costs and utilization since 2018. The full release … Read more
The Patented Medicine Prices Review Board (PMPRB) has launched a 90-day consultation period where stakeholders and interested Canadians are invited to read its new Draft Guidelines and provide feedback before March 19, 2025. The deadline for providing written submissions through the PMPRB website is March 19, 2025. Contact PMPRB.Consultations.CEPMB@pmprb-cepmb.gc.ca.
Health Minister Mark Holland (Ajax, Ont.) tabled the 2023 Annual Report of the Patented Medicine Prices Review Board with the Clerks of the Senate and the House of Commons. The 2023 Annual Report outlines trends in the prices and sales of patented medicines in Canada. Sales of patented medicines in 2023 were $19.9 billion and … Read more
The latest edition of Meds Pipeline Monitor, from the Patented Medicine Prices Review Board, provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may significantly impact clinical practice or drug spending in the coming years. There were over 12,000 drugs in the pipeline in 2023, increasing by an average … Read more
